A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs MEDI 0382 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 27 Feb 2018 to 22 Jan 2018.
    • 04 Dec 2017 Planned primary completion date changed from 27 Feb 2018 to 22 Jan 2018.
    • 04 Dec 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top